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OBJECTIVEdThe pathogenesis of brain disorders in type 1 diabetes (T1D) is multifactorial
and involves the adverse effects of chronic hyperglycemia and of recurrent hypoglycemia. Kidney-
pancreas (KP), but not kidney alone (KD), transplantation is associated with sustained normo-
glycemia, improvement in quality of life, and reduction of morbidity/mortality in diabetic
patients with end-stage renal disease (ESRD).
RESEARCH DESIGN AND METHODSdThe aim of our study was to evaluate with
magnetic resonance imaging and nuclear magnetic resonance spectroscopy (
1H MRS) the cere-
bralmorphologyandmetabolismof15ESRDplusT1Dpatients,23patientswithESRDplusT1D
after KD (n = 9) and KP (n = 14) transplantation, and 8 age-matched control subjects.
RESULTSdMagnetic resonance imaging showed a higher prevalence of cerebrovascular dis-
easeinESRDplusT1Dpatients(53%[95%CI36–69])comparedwithhealthysubjects(25%[3–6],
P =0 . 0 4 ) .B r a i n
1H MRS showed lower levels of N-acetyl aspartate (NAA)-to-choline ratio in ESRD
plus T1D, KD, and KP patients compared with control subjects (control subjects vs. all, P , 0.05)
andofNAA-to-creatineratioinESRDplusT1DcomparedwithKPandcontrolsubjects(ESRDplus
T1D vs. control and KPsubjects, P # 0.01). The evaluation of the most common scores of psycho-
logicalandneuropsychologicalfunctionshowedagenerallybetterintellectualproﬁleincontroland
KP subjects compared with ESRD plus T1D and KD patients.
CONCLUSIONSdDiabetes and ESRD are associated with a precocious form of brain im-
pairment, chronic cerebrovascular disease, and cognitive decline. In KP-transplanted patients,
mostofthesefeaturesappearedtobenearnormalizedaftera5-yearfollow-upperiodofsustained
normoglycemia.
Diabetes Care 35:367–374, 2012
I
npatientswithtype1diabetes(T1D),a
hyperglycemia-related generalized
multiorgan failure (e.g., eye, kidney,
central/peripheral nervous system, and
cardiovascular system) is evident (1,2). A
reduction in the volume of the cerebral
cortexand a signiﬁcant loss in neocortical
neurons are also present in mice with
streptozotocin-induced hyperglycemia
(3).Diffusecentralnervoussystemchanges
have been documented among patients
with T1D: neuronal and axonal general-
ized lesions were reported at multiple
sites, such as brain, optical nerve, and
posterior and anterior horns of spinal
cord (4). Neuropsychological tests per-
formed in diabetic patients have demon-
strated that the longer the exposure to
hyperglycemia, the more signiﬁcant the
impairment of superior brain functions
(1,2). Patients with so-called primary di-
abetic encephalopathy experience a re-
duction in mnemonic, abstract reasoning,
problem-solving, and hand-eye coordi-
nation abilities and an increased risk of
Alzheimer disease (5–7). Furthermore,
among patients with T1D a neurophysi-
ologic modiﬁcation with a diffuse slow-
ing in electroencephalographic tracks,
somatosensory/motor evoked potentials,
and brainstem auditory evoked poten-
tials has also been reported (8). The de-
gree of these changes is associated with
metabolic control; thus, tight glycemic
control is the only available option to slow
or prevent an early cognitive decline and
possibly dementia (3,8–10). Recurrent hy-
poglycemic episodes are likely to play
ar o l ei nd e c l i n eo fc o g n i t i v ef u n c t i o n sa s
well (3,6,11–14). Thus far, various imag-
ing techniques have been used to gain in-
sightintothediabeticbrain;amongthem,
an important role is played by proton
magnetic resonance spectroscopy (
1H
MRS).
1HMRSisanoninvasivetechnique
capable of detecting metabolic changes in
normal-appearing magnetic resonance im-
aging (MRI) examinations by allowing the
measurement of total creatine (associated
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Pathophysiology/Complications
ORIGINAL ARTICLEwithenergymetabolismandconsideredan
internal standard), choline-containing
compounds (Cho) (having an important
role in the turnover of cellular membrane),
and N-acetyl aspartate (NAA) (a marker
of neuronal density and function), whose
relative decrease has been attributed to
neuroaxonal loss in number and function
(15,16). Kidney-pancreas (KP) but not
kidney-alone (KD) transplantation has
been shown to be capable of halting the
progression and in many cases reversing
diabetes complications (17,18). Con-
versely, no studies are available thus far
ontheeffectsofKPtransplantationonthe
central nervous system. The aim of our
study was to assess the effect of KD and
KP transplantation on morphological
(e.g., brain volume), metabolic (e.g.,
neuronal/assonal modiﬁcations as eval-
uated with
1HM R Sp a r a m e t e r s ) ,a n d
functional (e.g., psychological and neuro-
psychologicalabnormalities)centralnervous
systemfeaturesgenerallycharacterizingT1D
patients’centralnervoussystem.Wethus
carried out brain MRI, localized single-
voxel spectroscopy, and nonlocalized
whole-brain NAA (WBNAA) spectroscopy
in patients with end-stage renal disease
( E S R D )a n dT 1 Da n di nK D -a n dK P -
transplanted patients after ;5 years of
follow-up. Our hypothesis was that in
the long term, the persistence of normo-
glycemia will be able to halt the progres-
sionandpotentiallytonormalizesomeof
the central nervous system abnormalities
associated with T1D, thus conﬁrming
that diabetes complications are not irre-
versible.
RESEARCH DESIGN AND
METHODSdWe enrolled 38 patients
with T1D, admitted to our center for
posttransplantation routine analysis and
with at least 3 years of follow-up, to be
scanned via MRI and MRS. Fifteen pa-
tients were on hemodialysis (ESRD plus
T1D), 9 had received a KD transplanta-
tion, and 14 had a simultaneous KP
transplantation. Eight normal volunteers
of similar age and sex (control subjects)
were studied as well. Infectious diseases,
septic states, elevated inﬂammatory mark-
ers,systemic immunologicconditions,and
history of cerebrovascular disease (either
transitory ischemic attack or stroke) were
considered exclusion criteria for participa-
tion in the study. The general character-
isticsofourparticipants,dividedbygroup,
are shown in Table 1.
Immunosuppression
Organs for transplantation were obtained
from cadaveric donors through the organ
procurement agency Nord Italia Trans-
plant.TheKDandKPgroupsweresimilar
for human leukocyte antigen matches,
pretransplant panels of reactive antibod-
ies, cold ischemia time, rates of kidney
rejection,cytomegalovirusinfection,donor
age, and rate of lymphoproliferative dis-
ease posttransplant. Patients received the
following immunosuppressive treatment:
antithymoglobulin [IMTIX SANGSTAT
(UK)], cyclosporine (target blood trough
levels between 100 and 250 ng/mL), or
FK506 (target blood levels between 10
and 15 ng/mL), mofetilmycophenolate
(0.5–2 mg/day), and prednisone (5–10
mg/day). Steroids were tapered and then
withdrawn within 6 months after trans-
plant.
Magnetic resonance protocols
MRI and
1H MRS were performed using a
1.5T scanner (Vision; Siemens, Erlangen,
Germany), with a head-dedicated coil.
During a single session, the following se-
quences were obtained:
c Axial dual-echo turbo-spin echo pro-
ton density and T2-weighted images
(repetition time [TR] 2,600 ms, echo
time [TE] 14/96 ms, ﬂip angle 1808,2 0
contiguous 5-mm thick axial slices,
200 3 512 matrix, ﬁeld of view (FOV)
240 mm, two acquisitions, scan time
3m i na n d3 4s ) .
c Axial ﬂuid-attenuated inversion recov-
ery images (TR 9,999 ms, TE 105 ms,
ﬂip angle 1808, 20 slices, 5-mm slice
thickness, 0.30 cm gap, 182 3 356
matrix, FOV 240 mm, one acquisition,
scan time 4 min and 29 s).
c Axial spin echo T1-weighted images
(TR 600 ms, TE 14 ms, ﬂip angle 708,
20 slices, 5-mm slice thickness, 0.20 cm
gap, 173 3 256 matrix, FOV 240 mm,
Table 1dDemographic and metabolic characteristics of our patients
Control subjects
ESRD
plus T1D KD KP P
n 81 591 4
Male/female 2/6 13/2 5/4 11/3 NS
Age (years) 42.0 6 5.0 48.7 6 7.3 46.0 6 6.5 43.2 6 5.5 NS
Years of T1D d 31.6 6 8.2 35.8 6 6.6 30.1 6 6.8 NS
Years of ESRD d 7.7 6 5.5 6.9 6 2.8 11.2 6 3.6 NS
Duration of transplantation
(years) dd 3.2 6 2.9 5.4 6 3.1 NS
Total cholesterol (mg/dL) 181.0 6 17.2 166.0 6 37.1 192.6 6 33.1 178.7 6 25.4 NS
HDL cholesterol (mg/dL) 56.8 6 10.6 52.8 6 13.6 52.7 6 18.3 57.1 6 14.5 NS
Triglyceride (mg/dL) 82.9 6 5.4*x 157.4 6 85.7*# 119.2 6 50.6x 96.2 6 20.2# 0.01*, 0.04x,0 . 0 0 7 #
HbA1c (%) 5.0 6 0.1*x^7 . 9 6 1.5*# 7.9 6 1.3x8 5.8 6 0.9#8^ ,0.0001*#x, 0.01^, 0.00028
Fasting glucose (mg/dL) 86.6 6 4.6*x 200.3 6 86.4*# 183.8 6 65.2x8 83.0 6 15.8*#8 0.0004*, 0.0002x, ,0.0001#8
S-creatinine (mg/dL) 0.8 6 0.1*x#8 . 0 6 2.5*8^1 . 5 6 0.9x8 1.2 6 0.3#^ ,0.0001*8^, 0.03x,0 . 0 0 3 #
Cerebrovascular alterations 2/8 (25)* 8/15 (53) 5/9 (55) 7/14 (50) ,0.05 vs. all*
Cyclosporine/FK506 dd 5/4 10/4 d
Cyclosporine (ng/mL) dd 133.8 6 64.7 140.2 6 37.5 d
FK506 (ng/mL) dd 15.2 6 4.0 15.0 6 3.5 d
Data are means 6 SD, n/n,o rn/n (%) unless otherwise indicated.
368 DIABETES CARE, VOLUME 35, FEBRUARY 2012 care.diabetesjournals.org
Magnetic resonance in KP-transplanted patientsone acquisition, scan time 1 min and
47 s).
c Coronalspin echoT1-weighted images
(TR 600 ms, TE 14 ms, ﬂip angle 708,
20 slices, 5-mm slice thickness, 0.20
cm gap, 173 3 256 matrix, FOV 240
mm, one acquisition, scan time 1 min
and 47 s).
The entire pool of images was ana-
lyzed by an experienced neuroradiologist
to detect the presence of white matter le-
sions suggesting a process of leukoaraiosis
on the basis of micro- and macroangi-
opathy during the clinical course of di-
abetes (18). A diagnosis of cerebrovascular
disease was formulated according to the
literature (12). T1 axial images of each
participant were transferred to an off-line
w o r k s t a t i o n( S u nS p a r c s t a t i o n ;S u nM i -
crosystem, Mountain View, CA) for brain
volume assessment performed by a single
observer,who wasunawareofthe identity
and group of the study participants. This
procedure used a segmentation technique
based on a signal intensity thresholding
andcharacterizedbyhighintraraterrepro-
ducibility (13).
Brain volume was measured from T1-
weighted images via use of a seed-growing
technique for brain tissue segmentation.
This method is based on signal-intensity
thresholding. A seed point was positioned
in different parts of cerebral tissue, and
from this seed, a region of interest (ROI)
was grown. This ROI contained all connec-
ted pixels within two given signal-intensity
values. The upper and lower signal inten-
sityforseedgrowingcouldbeinteractively
changed on a section-by-section basis.
If the ROI crossed the border of interest,
a manual boundary was drawn to limit the
seed growing. This procedure was partic-
ularly useful in some anatomical regions
suchasinthefrontal-basalregionsorinthe
polar portion of temporal lobes where
brain tissue is close to the bone or when
the exclusion of ventricular plexus and
cranial nerves is needed (e.g., optic nerves
and optic tracts, which are close to the
parenchyma). The process was repeated
for each slice until the entire brain volume
was covered from the bulb to the vertex.
At the end of the segmentation process,
tissue volume was calculated by multiply-
ing the number of pixels included in the
ROI for the voxel size. All brain-volume
measurements were done by the same
operator, reducing intraindividual error
and giving good accuracy (13).
Single-voxel spectroscopy magnetic
resonance was performed positioning a
single voxel in the bifrontal cortex, in its
ﬁrst circumvolution, including gray and
white matter, with its posterior border at
the level of the precentral gyrus. The
dimensions of the voxel were 40 3 30
3 20 mm (anteroposterior 3 right-left
3 craniocaudal) (Fig. 1B), with TE 135
Figure 1dAxial ﬂuid-attenuated inversion recovery acquisitions showing hyperintense lesions suggestive of chronic cerebrovascular disease in
a control subject (A), an ESRD plus T1D patient (B), and a KP-transplanted patient (C). Single-voxel
1H MRS brain examination shows Cho, total
creatine(Cr),andNAAspectrainacontrolsubject(D),inanESRDplusT1Dpatient(E),andinaKPpatient(F).(Ahigh-qualitycolorrepresentation
of this ﬁgure is available in the online issue.)
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Fiorina and Associatesms,256acquisitions,andscantime6min
and 31 s. The position of the voxel was
case bycaseadjusted by theoperator,giv-
ing particular attention to avoid as much
as possible contamination by cerebrospi-
nal ﬂuid. Spectra were separately ana-
l y z e do nt h em a g n e t i cr e s o n a n c e
scanner toolbox by the same operator re-
gardless of to whom they belonged. Cho,
creatinine, and NAA peaks were calcu-
lated and then their integral function
was solved by automatic and manual
measurement. Results were expressed as
ratios: NAA to creatinine, Cho to creati-
nine, and NAA to Cho.
WBNAA spectroscopy was performed
using the following parameters: TR
10,000 ms, TE 15 ms, FOV 240 mm, 8
acquisitions, and acquisition time 2 min
and 41 s. Five consecutive measurements
were obtained from each subject in order
to get the best quality spectra, as previ-
ously described by Gonen and Grossman
(14). Consequently, the whole scanning
timeofnot-localizedMRSbecame 13min
and 25 s. Spectra were sent to an off-line
workstationandanalyzedbythesameop-
erator to avoid interindividual variability,
regardlessoftowhomthey belonged.IDL
5.3 WBNAA software (Research Systems,
Boulder, CO) was used to process the
spectra and calculate NAA peak. To get
an absolute amount of the entire cere-
bral NAA, it was necessary to scale NAA
peak integral against the one of a stan-
dard referee. The latter is represented by
a plexiglass phantom of spherical shape,
ﬁlled with water in which a solution of a
known concentrationofNAA (15 mmol/L,
corresponding to 2.63 g) and NaCl (130
mmol/L, corresponding to 7.6 g) is solved.
As the acquisition of the whole group of
transplanted and untransplanted ESRD
plus T1D and control subjects took a long
period and corruption of the phantom was
possible, more than one phantom was ob-
tained and measured. Each pathologic pa-
tient and each control subject were then
paired with the closest in-time phantom
measurement. It was then possible to cal-
culate the absolute NAA concentration
(AbsNAA) using the following equation, as
stated by Gonen and Grossman: AbsNAA
(millimoles per liter) = 15 3 [(Voltp/Voltf) 3
(Sp/Sf)], where Voltp and Voltf, respec-
tively, are patient/subject and phantom
voltage and Sp and Sf, respectively, are
patient/subject and phantom NAA peak
integral.Tocorrectforinterindividualvar-
iations in brain size, AbsNAA of each pa-
tient and healthy subject was divided by
brain volume, obtained, as described
above, using a seed-growing technique
based on signal-intensity thresholding.
The following equation was used to get an
absolutebrainNAAconcentration([NAA]):
[NAA] (millimoles per liter) = AbsNAA/Vp,
where Vp is brain volume.
Psychological and
neuropsychological tests
Psychological assessment focused on emo-
tional patterns and quality of life (QoL) of
patients. The ProﬁleofMoodState(POMS)
wasusedformeasuringpresentmoodstates
and disturbance symptoms, dissecting six
dimensions of mood including tension-
anxiety (POMS-T), depression-dejection
(POMS-D), anger-hostility (POMS-A),
vigor-activity (POMS-V), fatigue-inertia
(POMS-S), and confusion-bewilderment
(POMS-C) (19). The questionnaire con-
sisted of 65 adjectives on a ﬁve-point
scale, ranging from “not at all” to “ex-
tremely,” with which the patients indi-
cated their mood over the past week. To
assess the QoL of patients, the LEIPAD test
was administered (20). Forty-nine self-
assessmentitems,31ofwhichweregrouped
into seven subscales such as physical func-
tion,self-care,depressionandanxiety,cog-
nitive functioning, social functioning,
sexual functioning, and life satisfaction,
were administered to the patients; the re-
maining 18 items served as moderators for
assessing the inﬂuenceofsocialdesirability
factors and personality characteristics on
the seven scores obtained previously.
Neuropsychological evaluation was
carried out, in one session, examining
childhood intellectual failures, global
cognitive efﬁciency, language, attention,
reasoning, and verbal/visuospatial me-
mory. History of psychiatric disorders
and childhood intellectual failures were
considered exclusion criteria for joining
the study, and an intelligence test was
used to exclude primary cognitive deﬁ-
ciencies. The Mini Mental State Exami-
nation was used for analyzing patients’
global cognitive abilities (21). Language
functioning was evaluated with token
andwordﬂuencytests(22).Attentionabil-
ities were analyzed with the Stroop test,
which evaluated selective attention and
inhibitoryability,andthePacedAuditory
Serial Addition Test (PASAT), which
evaluated sustained attention and the
speed of information processing (23,24).
Verbal and visual short-term memory
function was assessed through verbal
span and Corsi span test, while verbal
long-term memory was assessed with
short story recall (25). Finally, abstract
reasoning and categorization abilities
were evaluated with the Wisconsin card-
sorting test (48-card form) (26).
Statistical analysis
Continuous variables are presented as
means 6 SD for variables with a normal
distribution and as median (interquartile
range) for variables without a normal
distribution. Categorical variables are
presentedasproportions(95%CI).Con-
tinuous variables with a normal distribu-
tion were compared using the two-tail
Student t test for unpaired data (two
groups) or one-way ANOVA (three or
more groups). Continuous variables
without a normal distribution were com-
pared using the Mann-Whitney U test
(two groups) or the Kruskall-Wallis test
(three or more groups). Categorical varia-
bles werecompared usingthe x
2test ifthe
number of observations in each cell was
ﬁve or more or Fisher’s exact test if the
number of observations in any cell was
lessthan ﬁve.A P value,0.05was consid-
ered statistically signiﬁcant. CI was esti-
mated using the exact binomial. Data
analysiswasperformedusingStata,version
11.1 (StataCorp, College Station, TX).
RESULTS
Characteristics of study participants
The general characteristics of our partic-
ipants, divided by group, are shown in
Table 1. The four groups were similar for
sex and age, and no major differences in
T1D and ESRD duration were found. KD
and KP patients had similar follow-up
time after organ transplantation and
were not different for antihypertensive
or antidislipidemic therapies (Table 1)
(data not shown). ESRD plus T1D and
KD groups were on chronic insulin ther-
apy, while theKP group conserved an op-
timal glucometabolic control (Table 1)
(data not shown). As expected on the ba-
sis of the selection criteria, fasting glucose
(control subjects 86.6 6 4.6 mg/dL,
ESRD plus T1D 200.3 6 86.4 mg/dL, KD
183.8 6 65.2 mg/dL, and KP 83.0 6 15.8
mg/dL; control subjects vs. ESRD plus
T1D/KD, P , 0.001; KP vs. ESRD plus
T1D/KD, P , 0.0001) and HbA1c (con-
trol subjects5.06 0.1%, ESRD plus T1D
7.961.5%,KD7.961.3%,andKP5.86
0.9%;controlsubjectsvs.all,P # 0.01;KP
vs. ESRD plus T1D/KD, P , 0.001) levels
were signiﬁcantly lower in the control
subjects and KP group than in the ESRD
plusT1DandKDgroups(Table1).Serum
creatinine was signiﬁcantly higher in the
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KD, and KP groups (control subjects
0.8 6 0.1 mg/dL, ESRD plus T1D 8.0 6
2.5 mg/dL, KD 1.5 6 0.9 mg/dL, and KP
1.2 6 0.3 mg/dL; ESRD plus T1D vs. all,
P , 0.0001; control subjects vs. KD/KP,
P , 0.05) and triglycerides were signif-
icantly higher in the ESRD plus T1D
group than in the control, KD, and KP
groups(controlsubjects82.965.4mg/dL,
ESRD plus T1D 157.4 6 85.7 mg/dL, KD
119.2 6 50.6 mg/dL, and KP 96.2 6 20.2
mg/dL; control subjects vs. ESRD plus
T1D/KD, P , 0.05; ESRD plus T1D vs.
KP, P = 0.007) (Table 1).
Conventional MRI
Cerebral volume. Mean cerebral volume
was similar between the four groups of
participants, although slightly higher brain
volumeswerefoundintheKP-transplanted
subjects compared with ESRD plus T1D
and KD patients (control subjects 1,197.0
6 98.2 mL, ESRD plus T1D 1,099.0 6
88.2 mL, KD 1,096.0 6 111.6, and KP
1,135.0 6 128.3 mL; not signiﬁcant)
(Figs. 1A–C and 2A).
Chronic cerebrovascular disease. On
thebasisoftheconventionalMRI,among
patients with diabetes 20 of 38 had man-
ifestations related to chronic cerebrovascu-
lar disease compared with 2 of 8 control
subjects (ESRD plus T1D 53% [95% CI
36–69] vs. control subjects 25% [3–6]; P =
0.04)(Fig.1A–CandTable1),withoutma-
jor differences between ESRD plus T1D
and KD/KP (Table 1).
MRS
Localized MRS–single-voxel spectros-
copy. A low NAA-to-Cho ratio (which is
an index of neuroaxonal loss or damage
associatedwithgliosis)(27,28)wasfound
a m o n gE S R Dp l u sT 1 D ,K D ,a n dK P
groups compared with control subjects
(controlsubjects 2.060.2arbitraryunits
[ A U ] ,E S R Dp l u sT 1 D1 . 66 0.6 AU, KD
1.76 0. 2AU ,an dK P1. 76 0.3AU; con-
trolsubjects vs. all, P , 0.05)(Figs. 1D–F
and 2D). The NAA-to-creatinine ratio,
suggesting neuronal loss or damage
when decreased (29), was signiﬁcantly
lower in the ESRD plus T1D group com-
pared with the control subjects and KP
group (control subjects 2.1 6 0.2 AU,
ESRD plus T1D 1.9 6 0.1 AU, KD
1.9 6 0 . 2A U ,a n dK P2 . 06 0.2 AU;
ESRD plus T1D vs. control subjects/KP,
P # 0.01) (Figs. 1D–F and 2E). Finally,
the Cho-to-creatinine ratio, which has
previouslybeenfoundtobehigherinpa-
tients with diabetes-related brain gliosis
(30), was similar between groups (Figs.
1D–F and 2F). An inverse linear correla-
tion between HbA1c and NAA/creatinine
regardless of kidney function was found
(r = 20.353, P , 0.03) (data not
shown).
Nonlocalized MRS (WBNAA spectros-
copy). NAAisaneuronalmarker,andits
total concentration decrease indicates
neuroaxonal loss/impairment (15,16).
In our sample, WBNAA mean content
was similar in all groups (control sub-
jects 14.5 6 1.5 AU, ESRD plus T1D
13.8 6 1.6 AU, KD 13.8 6 3.2 AU, and
KP 14.5 6 1.4 AU; not signiﬁcant) (Figs.
1D–F and 2B). AbsNAA was similar in the
four groups of participants (data not
shown), and overlapping results were
f o u n da sw e l lf o r[ N A A ]w h e nA b s NAA
values were corrected for subjects’ brain
volumetoadjustforinterindividualvar-
iations (control subjects 12.1 6 0.6 AU,
ESRD plus T1D 12.6 6 1.8 AU, KD
12.5 6 2.0 AU, and KP 12.9 6 1.6
AU; not signiﬁcant) (Figs. 1D–F and
2C).
Psychological and
neuropsychological assessment
The psychological assessment evaluated the
emotional axis and QoL of patients through
POMS and LEIPAD tests, respectively
(19,20). The POMS test, examining six
different dimensions of mood, revealed
a signiﬁcant higher score for POMS-D be-
tween control subjects and KD patients
and a signiﬁcantly lower score in ESRD
plus T1D compared with KP subjects (con-
trol subjects 8.6 6 0.9, ESRD plus T1D
13.5 6 11.1, KD 5.9 6 8.9, and KP 2.8 6
3.0; control subjects vs. KD, P = 0.0007;
ESRDplusT1Dvs.KP,P=0.002)(Table2).
POMS-S showed a signiﬁcant difference
among control subjects and KD and KP
patients and in ESRD plus T1D compared
with KP subjects (control subjects 9.0 6
2.2, ESRD plus T1D 8.7 6 5.5, KD 4.6 6
2.8,andKP3.962.8;controlsubjects vs.
KD/KP, P , 0.01; ESRD plus T1D vs. KP,
P = 0.01). No differences in POMS-T, -A,
Figure 2dMRIand
1HMRSevaluationwereperformed inthe four groupsof patients.Nodifferencesbetween groupswereevidentforbrainvolume
(A), WBNAA (B), and [NAA] (C). NAA/Cho (D) and NAA/creatinine (Cr) (E)w e r es i g n i ﬁcantly lower in ESRD plus T1D patients compared with
control (CTRL) subjects and were near normalized in KP- but not KD-transplanted patients. The Cho-to-creatinine ratio is shown as well (F).
care.diabetesjournals.org DIABETES CARE, VOLUME 35, FEBRUARY 2012 371
Fiorina and Associates-V and -C were detected in our sample
(Table 2). The LEIPAD test revealed a sig-
niﬁcantly lower score (where lower is bet-
ter) for physical function in control
subjects compared with ESRD plus T1D
subjects, while transplanted patients (KD
and KP) showed a lower score compared
with ESRD plus T1D patients (control
subjects 2.4 6 1.1, ESRD plus T1D
7.2 6 1.7, KD 5.7 6 3.4, and KP 3.8 6
2.0; ESRD plus T1D vs. control subjects/
KP,P#0.001)(Table2).Thesexualfunc-
tion index was found to be signiﬁcantly
lower (where higher is better) in control
subjects compared with KD patients (con-
trol subjects 1.8 6 0.8, ESRD plus T1D
3.2 6 1.4, KD 3.8 6 1.3, and KP 2.2 6
1.2;controlsubjectsvs.KD,P=0.02)(Ta-
ble 2). Finally, life satisfaction score was
signiﬁcantly lower (where lower is better)
in control subjects compared with ESRD,
KD, and KP patients (control subjects
2.4 6 0.5, ESRD plus T1D 7.9 6 3.9,
KD 6.5 6 2.9, and KP 5.5 6 2.0; control
subjects vs. all, P , 0.01) (Table 2). Other
scores showed a general better trend in
KP-transplanted patients compared with
ESRDplusT1DandKDpatients(Table2).
Patients’ neuropsychological evaluation
conﬁrmed that KP and KD subjects expe-
rienced beneﬁts from transplantation
compared with ESRD plus T1D patients
inalmostthewholepooloftests(Table2).
Particularly, KP (but not KD) patients ob-
tained better results in phonemic word
ﬂuency and the PASAT test, respectively,
compared with results in ESRD plus T1D
patients (control subjects 38.6 6 6.5,
ESRD plus T1D 24.9 6 9.4, KD 34.7 6
8.9, and KP 33.1 6 6.4; ESRD plus T1D
vs. control subjects/KP, P , 0.05; control
subjects 41.4 6 9.1, ESRD plus T1D
29.7 6 14.2, KD 44.7 6 13.2, and KP
45.2 6 10.0; ESRD plus T1D vs. KP, P =
0.008) (Table 2). The color naming (con-
trol subjects 14.0 6 3.4, ESRD plus T1D
26.3 6 5.5, KD 24.9 6 4.1, and KP
25.4 6 5.2; control subjects vs. all, P #
0.001) and the word-color interference
variantsoftheStrooptest(controlsubjects
17.2 6 5.5, ESRD plus T1D 40.0 6 9.9,
KD 47.9 6 15.1, and KP 35.8 6 5.5; con-
trol subjects vs. all; P , 0.01) were higher
(i.e.,worse)inESRDplusT1D,KD,andKP
patients compared with control subjects
(Table 2). The color-color interference
Stroop test showed signiﬁcantly lower
scores (where lower is worse) in ESRD
plus T1D and KD patients compared
with control subjects (control subjects
36.8 6 21.4, ESRD plus T1D 62.7 6
10.4, KD 61.7 6 17.1, and KP 50.4 6
13.0; control subjects vs. ESRD plus
T1D/KD, P # 0.05) (Table 2). A valuation
of the number of errors made by the pa-
tients while performing the three sections
of the Stroop test showed a signiﬁcantly
lower number of errorsincontroland KP
s u b j e c t sc o m p a r e dw i t hE S R Dp l u sT 1 D
and KD subjects (control subjects 0.6 6
1.3,ESRDplusT1D 6.7 6 4.0,KD5.66
3.0, and KP 2.7 6 2.0; control subjects
vs. all, P , 0.01; ESRD plus T1D vs.
KP, P = 0.009; KD vs. KP, P = 0.025)
(Table 2).
Table 2dPsychological and neuropsychological evaluations
Control subjects ESRD plus T1D KD KP P
n 51 5 9 1 4
POMS-T 10.8 6 1.3 10.9 6 7.5 5.6 6 4.2 6.8 6 5.3 NS
POMS-D 8.6 6 0.9*x 13.5 6 11.1x 5.9 6 8.9 2.8 6 3.0*x 0.0007*, 0.002x
POMS-A 10.2 6 2.5 11.6 6 8.4 4.9 6 4.6 5.6 6 5.8 NS
POMS-V 14.0 6 3.1 13.4 6 6.1 12.2 6 5.9 18.1 6 6.8 NS
POMS-S 9.0 6 2.2*x 8.7 6 5.5# 4.6 6 2.8* 3.9 6 2.8*x# 0.01*, 0.002x,0 . 0 1 #
POMS-C 4.8 6 1.1 8.2 6 4.4 6.1 6 2.6 4.8 6 3.7 NS
Physical function 2.4 6 1.1* 7.2 6 1.7*x 5.7 6 3.4 3.8 6 2.0x 0.0002*, 0.001x
Self-care 0.2 6 0.4 1.1 6 1.3 2.0 6 3.1 1.2 6 2.0 NS
Depression and anxiety 2.0 6 0.7 3.6 6 2.5 1.8 6 2.1 2.1 6 1.9 NS
Cognitive functioning 2.2 6 0.4 3.6 6 2.7 4.3 6 1.2 2.9 6 2.1 NS
Social functioning 2.4 6 1.1 3.0 6 2.3 3.2 6 2.2 3.7 6 2.0 NS
Sexual functioning 1.8 6 0.8* 3.2 6 1.4 3.8 6 1.3* 2.2 6 1.2 0.02*
Life satisfaction 2.4 6 0.5*x#7 . 9 6 3.9* 6.5 6 2.9x 5.5 6 2.0# 0.01*, 0.01x, 0.004#
MMSE 29.0 6 0.7 28.3 6 1.0 28.9 6 1.2 29.3 6 1.4 NS
Token 33.4 6 0.8 32.6 6 3.7 32.4 6 2.4 34.1 6 2.0 NS
Phonemic ﬂuency 38.6 6 6.5* 24.9 6 9.4x 34.7 6 8.9 33.1 6 6.4*x 0.01*, 0.02x
Semantic ﬂuency 49.2 6 7.3 41.4 6 12.2 41.9 6 12.4 50.8 6 8.3 NS
Long-term verbal memory 16.8 6 1.9 11.4 6 2.8 14.9 6 2.1 13.0 6 4.4 NS
Short-term verbal memory 4.9 6 0.5 5.7 6 1.2 5.0 6 1.0 5.9 6 1.1 NS
Corsi 5.1 6 0.8 4.7 6 0.6 4.6 6 0.8 5.1 6 1.0 NS
PASAT 41.4 6 9.1 29.7 6 14.2* 44.7 6 13.2 45.2 6 10.0* 0.008*
Stroop 1 14.0 6 3.4*x#2 6 . 3 6 5.5* 24.9 6 4.1x 25.4 6 5.2# 0.001*, 0.0006x,0 . 0 0 0 4 #
Stroop 2 17.2 6 5.5*x#4 0 . 0 6 9.9* 47.9 6 15.1x 35.8 6 5.5# 0.001*, 0.002x, ,0.0001#
Stroop 3 36.8 6 21.4*x 62.7 6 10.4* 61.7 6 17.1x 50.4 6 13.0 0.018*, 0.05x
Stroop error 0.6 6 1.38 6.7 6 4.0* 5.6 6 3.0x 2.7 6 2.0*x ,0.01 vs. all8, 0.009*, 0.025x
WCST 6.0 6 0.0 6.0 6 0.0 5.9 6 0.4 5.7 6 1.1 NS
Dataaremeans6SDunlessotherwiseindicated.Psychologicalevaluations:theproﬁleofmoodstateanalysisofdepression-dejectionandfatigue-inertiatractsandthe
physical function evaluation showed better results in KP-transplanted patients (but not in KD patients) compared with ESRD plus T1D. Neuropsychological eval-
uation: phonemic word ﬂuency, PASAT, and Stroop tests were near normalized in KP-transplanted patients (but not in KD patients) compared with ESRD plus T1D
patients. MMSE, Mini Mental State Examination; Stroop 1, Stroop test color naming; Stroop 2, Stroop test word-color interference; Stroop 3, Stroop test color-color
interference; WCST, Wisconsin card-sorting test.
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A linear correlation between HbA1c and
NAA/creatinine was evident in the en-
tire cohort of patients regardless of kid-
ney function (r = 20.353, P , 0.03)
(Supplementary Fig. 1, available in the
Supplementary Data).
CONCLUSIONSdThe pathogenesis
ofcerebraldisordersinT1Disstillunclear
but is thought to be multifactorial, involv-
ing chronic hyperglycemia and recurrent
hypoglycemia, which has been proved to
cause neuronal loss (31). In ESRD plus
T1D patients, KP transplantation is an ef-
fective treatment in increasing the QoL
and in reducing diabetes-related mortality
and morbidity (17,27,28). We analyzed
morphological, metabolic, and functional
featuresofthecentralnervoussystemin15
ESRD plus T1D, 9 KD, and 14 KP patients
and8controlsubjects.First,weperformed
MRIs, showing the higher prevalence of
chronic cerebrovascular disease in the
population of patients with ESRD plus
T1D. No major differences were observed
from a morphological point of view be-
tween transplanted patients and ESRD
p l u sT 1 Dp a t i e n t sa sp e r c e n t a g eo fv a s -
culopathy or brain volume. However,
through analysis of the relative levels of
NAA, Cho, and creatinine and their ratios
through localized single-voxel spectros-
copy, NAA-to-Cho and NAA-to-creatinine
ratios were shown to be signiﬁcantly lower
in ESRD plus T1D and transplanted pa-
tients compared with control subjects. A
reduced NAA-to-Cho ratio, as we found in
our diabetic population, which results from
the presence of elevated Cho-containing
compounds or a reduced NAA reso-
nance, could be interpreted as an index
of neuroaxonal loss/impairment associated
with diabetes-related gliosis (29,30). The
NAA-to-creatinine ratio is an index of neu-
ronallossordamage(29,30).Interestingly,
only KP patientsdnot KD patientsd
had NAA-to-creatinine values higher
than ESRD plus T1D patients, suggesting
apotentialreversibleeffectorroleexerted
by combined KP transplantation in im-
proving cerebral metabolic function in
the clinical course of diabetes-related
encephalopathy. Finally, we veriﬁed that
ourspectroscopicﬁndingswerecorrelated
with signs of psychological and neuropsy-
chological impairment. We found a signif-
icant improvement in mood proﬁle,
physical function, phonemic ﬂuency,
and attention abilities in KP, but not KD,
subjects compared with ESRD plus T1D
patients. Moreover, control subjects and
KP-transplanted patients showed a gener-
ally more conserved psychological and
neuropsychological attitude compared
with KD-transplanted and ESRD plus
T1Dpatients.Diabetesandhyperglycemia
are implicated in the genesis of early cog-
nitive decline and possibly dementia ow-
ing to multiple factors such as severe
hypoglycemia episodes, glucometabolic
disorders, blood-brain barrier damage,
and sustained ketoacidotic episodes, be-
ingabletoreduceNAA/creatininecerebral
content and myelination (9,32,33). In-
terestingly, HbA1c correlated with the
NAA-to-creatinine ratio, a good marker
of axonal/neuronal loss, conﬁrming the
closerelationshipbetweenglycometabolic
control and brain metabolic abnormalities
(19,20).Additionally,ESRDcausestheac-
cumulation of uremic toxins and induces
encephalopathy and cognitive impair-
ment, with symptoms ranging from mild
confusional states and sleep disorders to
deep coma (34). Hemodyalitic therapy
should be considered a cause as well, be-
ingabletoinducechronicdialysisenceph-
alopathy (35). By contrast, successful KP
transplantation has been shown to pro-
vide normoglycemia in the long term
and to halt the progression of diabetes
complications, reducing the extent of di-
abetic retinopathy, nephropathy, and en-
cephalopathy (18). Blood pressure,
cardiac function, and cholesterol are pos-
itively affected by KP transplantation as
well (36). Interestingly, we and others
have shown that these results were not
fully obtained with KD transplantation,
conﬁrming that normalizing hyperglyce-
mia is as important as the removal of
ESRD. The reason for the reduced life ex-
pectancy in patients with poorly con-
t r o l l e dT 1 Da n di nE S R Dp l u sT 1 D
patients has been studied extensively. Pre-
vious work has shown that severe platelet
functional abnormalities are evident in pa-
tients with ESRD plus T1D patients (37),
andthismaycauseapropensityfor cardio-
vascular and cerebrovascular diseases.
Uremia is also characterized by prolonged
bleeding time (38) and accelerated vascu-
lar calciﬁcation that clearly predisposes
uremic patients to vascular pathologic
events (39). It is interesting to observe
that KP transplantation, despite longer di-
alysisduration,hadthemostdramaticim-
provement in brain structure/function.
Finally, it is noteworthy that patients
who no longer need to inject insulin (e.g.,
who are using insulin pumps) and have
good metabolic control have been shown
to have improved mood (40); thus, our
observations could partially reﬂect this
rather than a real functional effect on the
brain.
Despite the cross-sectional limitation
of our study, which renders our observa-
tions preliminary and worthy of further
conﬁrmation, our results suggest that the
brain is another organ damaged by dia-
betesfromamorphologic,metabolic,and
functional point of view and that KP
transplantation is an effective approach
to ameliorating metabolic abnormalities.
1H MRS is a valuable tool for monitoring
the morphological and metabolic aspects
of the central nervous system in patients
with diabetes.
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